Spring Bank Pharmaceuticals Inc
Spring Bank Pharmaceuticals — F-star Therapeutics — Q3 2021 Earnings Presentation
26 slides from Spring Bank Pharmaceuticals's earnings presentation, Aug 12, 2021
Slide 1: Q3 2021 Next Generation Immunotherapies. Overcoming Cancer.
Q3 2021 Next Generation Immunotherapies. Overcoming Cancer. Exhibit 99.2
Slide 2: Forward-looking statements
Certain statements contained in this communication regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, known as the PSLRA. These
Slide 3: F-star at a Glance
Developing next generation immunotherapies to transform the lives of patients with cancer F-star at a Glance Validating Partnerships Natural human format for better manufacturing and safety “Plug & Play” versatility for rapid drug discovery Rational drug design: Four binding sites with tuneable affi
Slide 4: F-star's Potential to Deliver Investor Value
Successful, experienced team with 20 approved drugs F-star’s Potential to Deliver Investor Value Cash runway through multiple clinical milestones Key Financial Highlights* $81.6M Cash 20.6M Common Shares Outstanding *as of 30th June 2021 Four 2nd generation IO therapeutics in the clinic Funded by to
Slide 5: Experienced Management Team
Experienced Management Team Medical oncologist with 25+ years' experience in clinical research in Europe and US Experience in registrational studies, registration strategy and drug approval Louis Kayitalire CMO, MD 25+ years leading financial operations in public and private companies Proven track r
Slide 6: Four Differentiated Clinical Programs
Four Differentiated Clinical Programs FS120 Improving CPI and chemotherapy outcomes CONDITIONAL OX40/CD137 (4-1BB) DUAL STIMULATOR Ongoing Phase 1 trial in solid tumors MSD clinical supply agreement in place for pembrolizumab Update on accelerated dose titration in H2 2021 FS118 Overcoming and preve
Slide 7: Anticipated Future Data Milestones
Update on dose escalation FS222 Update on accelerated dose titration FS120 Safety, biomarker and preliminary efficacy data FS222 Update dose escalation SB 11285 FS120 Safety & biomarker update & initiation of Keytrudaâ cohorts FS222 Safety update to support initiation of PK/PD expansion cohorts Anti
Slide 8: FS118 Overcoming and preventing CPI-treatment failures
FS118 Overcoming and preventing CPI-treatment failures LAG-3 PD-L1
Slide 9: FS118: Profound Inhibition through LAG-3 Shedding
FS118: potent dual antagonist which induces LAG-3 shedding CONFIDENTIAL FS118: Profound Inhibition through LAG-3 Shedding “Given the uncertainty over LAG-3 ligands and coverage of blocking epitopes, cleavage is one way to ensure antagonism of all LAG-3 – ligand interactions.” Analyst FS118 Different
Slide 10: Building Opportunity - Expanding FS118 Clinical Strategy
Building Opportunity - Expanding FS118 Clinical Strategy FS118 overcomes Acquired Resistance to PD-1 blockade by inducing LAG-3 shedding while inhibiting PD-L1 FS118 avoids resistance to PD-1 blockade by preventing LAG-3 upregulation while inhibiting PD-L1 Hypotheses CPI naïve Post PD-1 CPI-naïve, P
Slide 11: FS118 Global Clinical Development Plan
FS118 Global Clinical Development Plan Ph I: First in Human Well tolerated up to 20 mg/kg with RP2D of 10 mg/kg Clinical benefit observed in tumors co-expressing LAG-3/PD-L1 59% DCR in PD-(L)1 acquired resistant patients Potent novel anti-LAG-3 mechanism leading to prolonged increased levels of solu
Slide 12: FS222 Improving outcomes in PD-L1 low tumors
CD137 PD-L1 FS222 Improving outcomes in PD-L1 low tumors
Slide 13: FS222 outperforms other bispecifics in primary immune cell assays
FS222 outperforms other bispecifics in multiple human primary immune cell assays Ref: Lakins et al, FS222, a Tetravalent Bispecific Antibody Targeting CD137 and PD-L1, is Designed for Optimal CD137 Interactions Resulting in Potent T cell Activation Without Toxicity, AACR 2021 Tetravalent bispecific
Slide 14: FS222 Phase Study Design: Seamless & Adaptive
FS222 Phase 1 Study Design: Seamless & Adaptive PART B Update H1 2022 Cohort expansion Planned PART A Update late 2021 Dose escalation & PK/PD expansion Confidence to proceed to indication specific expansion n = ~50 On-going Safety, PK/PD, Biomarkers n = 25+ Colorectal n = 25+ Ovarian n = 25+ NSCLC
Slide 15: FS120 Improving CPI and chemotherapy outcomes
OX40 CD137 FS120 Improving CPI and chemotherapy outcomes
Slide 16: FS120 Has a Differentiated Mechanism with Broad Potential For Combination
CONFIDENTIAL FS120 Has a Differentiated Mechanism with Broad Potential For Combination Improving anti-tumor immune response by “Triple Activation”*: Activates CD8+ and NK effector cells Increases CD4+ cell helper activity Destabilizes Tregs FS120 + anti-PD-1 combination FS120 + chemotherapy combinat
Slide 17: FS120: Phase 1 Study Design
PART B Initiate 2022 PART A Update Q3 2021 PART C FS120: Phase 1 Study Design Monotherapy dose escalation On-going PD-1 combo dosing frequency and dose escalation Planned Planned Combination dose expansion Determination of pharmacologically active dose n = 40+ n = ~30 n = 25+ n = 25+ n = 25+ NSCLC (
Slide 18: STING agonist SB 11285 Improving CPI outcomes
STING agonist SB 11285 Improving CPI outcomes
Slide 19: SB 11285 Phase Study Design
SB 11285 Phase 1 Study Design PART 1a SB 11285 appears well tolerated alone and with atezolizumab across all dose levels Heavily pre-treated tumors with some evidence of disease control PK profile aligns with likely immune cell uptake Biomarker data encourages further dose escalation PART 1b Continu
Slide 20: Anticipated Future Data Milestones
Update on dose escalation FS222 Update on accelerated dose titration FS120 Safety, biomarker and preliminary efficacy data FS222 Update dose escalation SB 11285 FS120 Safety & biomarker update & initiation of Keytrudaâ cohorts FS222 Safety update to support initiation of PK/PD expansion cohorts Anti
Slide 21: FSTX – A Stellar Outlook
CONFIDENTIAL FSTX – A Stellar Outlook Four ongoing programs with multiple clinical data readouts in next 24 months Continued validation of platform & pipeline through big pharma alliances Strong balance sheet and support from top-tier biotech investors © 2020 F-star. All rights reserved
Slide 22: F-star Potential Next Generation Immunotherapies
CONFIDENTIAL F-star Potential Next Generation Immunotherapies
Slide 23: Therapeutics - Thank you
THERAPEUTICS Thank you.
Slide 24: References
Platform: Designing Fcabs: well-expressed and stable high affinity antigen-binding Fc fragments. DOI: 10.1093/protein/gzx042 Generation of Fcabs targeting human and murine LAG-3 as building blocks for novel bispecific antibody therapeutics. DOI:10.1016/j.ymeth.2018.09.003. Bispecific antibodies: a m
Slide 25: Bispecific Differentiation Through Crosslinking, Clustering and Conditionality
Bispecific Differentiation Through Crosslinking, Clustering and Conditionality F-star mAb2 Traditional Antibody Antibody Combination Heterodimeric Bispecific Antibody Alternative Scaffold Bispecific Fragment Bispecific incl BITEs Bispecific crosslinking Conditional activity Tetravalent clustering Ig
Slide 26: FS118: Lead LAG-3 x PD-L1 Bispecific
CONFIDENTIAL FS118: Lead LAG-3 x PD-L1 Bispecific Format LAG-3 asset Company Anti-PD-(L)1 combination Lead indications Most Advanced Phase LAG-3 x PD-(L)1 FS118 (LAG-3 x PD-L1) F-star (FSTX) - SCCHN CPI naïve Ph 2 Tebotelimab (LAG-3 x PD-1) MacroGenics - Gastric Cancer, Gastroesophageal Junction Can